1 |
Zhang S, Wang C, Liu B, Lu Q, Shang J, Zhou Y, Jia J, Xu X, Rao H, Han B, Zhao T, Chen L, Xie M, Cui J, Du J, zeng J, huang N, Liu Y, Zhang L, Zhuang H, Cui F. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation. The Lancet Regional Health - Western Pacific 2023. [DOI: 10.1016/j.lanwpc.2023.100738] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
2 |
Zhang W, Xu C, Rui Y, Chen J, Chen T, Dai Y, Xu B, Hu Y, Chen J, Zhou Y. Efficacy of the hepatitis B vaccine alone in the prevention of hepatitis B perinatal transmission in infants born to hepatitis B e antigen-negative carrier mothers. Journal of Virus Eradication 2022. [DOI: 10.1016/j.jve.2022.100076] [Reference Citation Analysis]
|
3 |
Huang H, Zhang X, Luo Y, Chen J, Feng J, Dai Y, Hu Y, Zhou YH. The optimal interval for post-vaccination serological test in infants born to mothers with positive hepatitis B surface antigen. Hum Vaccin Immunother 2021;:1-5. [PMID: 34736352 DOI: 10.1080/21645515.2021.1992213] [Reference Citation Analysis]
|